Survival and multi-omics analysis of immunotherapy-based conversion treatment for initially unresectable gastric cancer.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have demonstrated efficacy in the treatment of resectable and advanced gastric cancer. However, their effectiveness in initially unresectable gastric cancer remains unclear. This study aims to evaluate the efficacy and elucidate the molecular mechanisms of conversion therapy utilizing ICIs in patients with initially unresectable gastric cancer.

Methods

This retrospective cohort study included patients with initially unresectable locally advanced or oligometastatic gastric cancer treated with ICIs-based therapy for conversion purposes. The primary endpoints were rates of complete pathological response (pCR), major pathological response (MPR), and R0 resection. Secondary endpoints included overall survival (OS), disease-free survi

SUBMITTER: Li S 

PROVIDER: S-EPMC12835316 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature